Active Biotech invites to Capital Markets Day


Active Biotech invites analysts, investors and media to Capital Markets Day on June 10, 2010.

When: Thursday, June 10, 2010 at2-4 p.m. CET.

Where: IVA Conference center, Grev Turegatan 16,


To attend:Please send name & contact details to or call
+46 (0)46 1920 00, no later than June 7

Active Biotech participants:

Tomas Leanderson, President & CEO

Hans Kolam, CFO

Göran Forsberg, VP Investor Relations & Business Development

Helén Tuvesson, Head of Preclinical development

Program:Overview of Active Biotech's project portfolio

The Capital Markets Day will also be available to follow via Active Biotech's website

For further information, please contact:

Hans Kolam, CFO

Phone: +46 (0)46 19 20 44


About Active Biotech

Active Biotech AB (NASDAQ OMX NORDIC: ACTI), headquartered in Sweden, is a biotechnology company with R&D focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Please visit for more information.

Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 08:30 am CET on May 18, 2010.

Active Biotech AB (org. no. 556223-9227)

P.O. Box 724, SE-220 07 Lund, Sweden

Tel +46 46-19 20 00

Fax +46 46-19 11 00

pdfActive Biotech invites to Capital Markets Day